Brown, Robert D.

Background: There are concerns about use of certain medications in patients with cavernous malformations (CM) being deleterious such as antithrombotics. In addition, there are select medications such as statins, vitamin D, and NSAIDs which theoretically may have a positive effect on endothelial leakiness. We aimed to determine whether certain medications taken prior to the diagnosis of CM influenced the presentation to medical attention. Methods: We established a prospective cohort of patients with clinically diagnosed CM in 2015. Patients are interviewed at inception and clinical records reviewed. Specifically, several medications are recorded including the use of: antithrombotics, NSAIDs, estrogen, Vitamin E, Vitamin D, SSRI, statin, and multivitamin. Patients are followed prospectively. Data continues to be collected annually on outcome events (bleeding) and ongoing medication use. Results: These results are on the first 103 patients entered into the database. Sixty-four (62.1%) patients are male and the average age at diagnosis is 39.1 years. Sixty-three (61.1%) presented with symptoms and 40 (38.9%) were incidental findings at first diagnosis. Patients taking NSAIDs (p=0.0468), Vitamin D (p=0.035), and statins (p=0.0163) were more likely to present with an incidental CM compared to those who presented symptomatically (hemorrhage, seizure or focal neurologic deficit). There was no significant difference in symptomatic vs. asymptomatic presentation in patients taking estrogens, warfarin, clopidogrel, SSRI, or vitamin E prior to presentation. Conclusion: This data supports the theoretic role of vitamin D, NSAIDS, and statin use in stabilization of endothelial permeability. Ongoing data collection and prospective follow up will allow us to determine if ongoing use of these medications plays a role in reducing risk of future hemorrhage.

Background: Current ischemic stroke (IS) subtyping systems are very labor-intensive and costly to implement in large samples. There is a need to develop phenotyping approaches for genetic and other studies that can be implemented using generally available items captured in electronic medical records. Objective: In this report, we seek to validate a simplified approach using results from a genetic association study. Specifically, the strength of association for known genetic signals in the NINDS Stroke Genetics Network study (SiGN) is compared between the established IS subtyping systems (TOAST and Causative Classification System (CCS) subtypes) and phenotyping based on a single item within the CCS. Methods: Non-mutually exclusive “Simple” IS subtypes were defined from single CCS items as follows: 1) Small vessel stroke- lacunar infarct on imaging (with no other imaging or other requirements); 2) large artery stroke - vascular imaging showing > 50% stenosis or <50% stenosis with plaque rupture or thrombosis judged to be due to atherosclerosis in clinically relevant artery; and 3) cardioembolic stroke - persistent or paroxysmal atrial fibrillation. We compared the GWAS signals using these definitions to the published SiGN GWAS results for TOAST and CCS, among those of European ancestry only. Results: The Table shows that, for loci significant in SiGN GWAS study, the “Simple” IS subtypes had similar strengths of association and p-values compared to results from TOAST and the causative and phenotypic CCS subtypes. Conclusions: “Simple” IS subtypes perform as well in GWAS analyses as more complex phenotyping systems and could potentially be derived through automated or semi-automated methods applied to electronic medical record systems. Since the ‘Simple” phenotypes were based on high quality CCS data, the current findings reflect optimal performance. Additional validation studies will be required for implementation in other settings.

Background: In CREST2, intensive medical management of subjects’ vascular risk factors is overseen by the site Principal Investigator (PI) and implemented by a designated Medical Management Physician (MMP) and coordinator. These physicians have different specialties and experience with risk factor management. We sought to determine the relationship between risk factor control and PI and MMP specialty. Methods: Data on 613 patients with at least 1 follow-up visit from 105 CREST2 sites were used for these analyses. CREST2 sites were categorized based on both PI specialty and MMP specialty. Specialty of the site-designated primary MMP was used for sites with more than one MMP. We compared the percentage of patients in target at last follow-up visit for the primary risk factors, LDL < 70 mg/dL and SBP <140 mm Hg, among PI specialties and MMP specialties, using the chi-square test. Results: The table shows the number of patients by PI and MMP specialty, as well as their control of SBP and LDL. There were no significant differences in control of SBP or LDL by PI specialty. There was a trend toward an association between LDL control and MMP specialty, with higher rates of LDL control at sites with Internal Medicine MMP specialists and lower rates of control with Vascular Surgery MMPs. SBP control rates were not significantly different across MMP specialties. Conclusions: In this early analysis of risk factor control in the CREST2 study, site PI and MMP specialty did not have a significant effect on LDL and SBP during follow-up. This suggests that protocol care pathways are generalizable to diverse physicians.

Objective: Aneurysm growth is considered predictive of future rupture of intracranial aneurysms. However, it is still unknown how accurately neuroradiologists can reliably detect incremental aneurysm growth using clinical magnetic resonance imaging (MRI) imaging. The purpose of this study is to assess the agreement rate of detecting aneurysm enlargement using generally used MRI imaging modalities. Methods: Three silicone flow phantom models each with eight aneurysms of various sizes in different sites were used in this study. The aneurysm models were identical except for an incremental increase in size of the 8 aneurysms ranging from 0.4mm to 2mm. The phantoms were imaged on 1.5 tesla (T) and 3T MRI units with both time-of-flight (TOF) and contrast enhanced magnetic resonance angiography (MRA). Three independent expert neuroradiologists measured the aneurysms in a blinded fashion utilizing different measurement approaches. The individual and agreement rate among the three experts in detecting aneurysm enlargement were calculated. Results: The average detection rate of any increase in any aneurysmal dimensions was 95.7%. The detection rate for the three readers (A, B and C) was 98.0%, 96.6% and 92.7%, respectively ( P =0.22). The detection rate in each MRI modality was 91.3% using 1.5 T TOF, 97.2% using 1.5T gadolinium (Gad), 95.8% using 3.0T TOF and 97.2% using 3.0T Gad ( P =0.31). As the incremental enlargement value increased, the detection rate for aneurysm enlargement increased. Use of Gad in 1.5T improved the detection rate in small incremental enlargement (e.g. 0.4 - 1mm) of the aneurysm ( P =0.04). The locations of the aneurysms also affected detection rate for aneurysm enlargement ( P <0.0001). Conclusions: The detection rate and interobserver agreement was very high for aneurysm enlargement of 0.4mm to 2 mm. Detection rate of any increase in any aneurysmal dimensions did not depend on the choice of MRI imaging modalities and measurement protocols.

Background and Purpose— Superficial siderosis (SS) is characterized by hemosiderin deposition in the superficial layers of the central nervous system and can be seen during postmortem examination or with iron-sensitive magnetic resonance imaging techniques. The distribution of SS may predict the probable underlying cause. This study aimed to report the prevalence and natural history of SS in a population-based study. Methods— Brain magnetic resonance imaging scans from the MCSA (Mayo Clinic Study of Aging), a population-based study of residents 50 to 89 years of age in Olmsted County, Minnesota, were reviewed. Participants with imaging consistent with SS were identified from 2011 through 2016. An inverse probability weighting approach was used to convert our observed frequencies to population prevalence of SS. Additional data abstracted included amyloid positron emission tomography, Apolipoprotein E genotype, coexisting cerebral microbleeds, and extent of SS. Results— A total of 1412 participants had eligible magnetic resonance imaging scans. Two participants had infratentorial SS, restricted to the posterior fossa. Thirteen participants had cortical SS involving the cerebral convexities (7 focal and 6 disseminated). Only 3 of the participants with cortical SS (23%) also had cerebral microbleeds. The population prevalence of SS was 0.21% (95% confidence interval, 0–0.45) in those 50 to 69 years old and 1.43% (confidence interval, 0.53–2.34) in those over 69 years old. Apolipoprotein E ε2 allele was more common in those with SS (57.1% versus 15.0%; P <0.001). Compared with participants without SS, those with SS were also more likely to have a positive amyloid positron emission tomographic scan (76.9% versus 29.8%; P <0.001). Conclusions— SS may be encountered in the general elderly population. The association with increased amyloid burden and Apolipoprotein E ε2 genotype supports cerebral amyloid angiopathy as the most common mechanism. Longitudinal follow-up is needed to evaluate the risk of subsequent hemorrhage in cases of incidentally discovered SS.

Background and Purpose— Multicenter clinical trials attempt to select sites that can move rapidly to randomization and enroll sufficient numbers of patients. However, there are few assessments of the success of site selection. Methods— In the CREST-2 (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trials), we assess factors associated with the time between site selection and authorization to randomize, the time between authorization to randomize and the first randomization, and the average number of randomizations per site per month. Potential factors included characteristics of the site, specialty of the principal investigator, and site type. Results— For 147 sites, the median time between site selection to authorization to randomize was 9.9 months (interquartile range, 7.7, 12.4), and factors associated with early site activation were not identified. The median time between authorization to randomize and a randomization was 4.6 months (interquartile range, 2.6, 10.5). Sites with authorization to randomize in only the carotid endarterectomy study were slower to randomize, and other factors examined were not significantly associated with time-to-randomization. The recruitment rate was 0.26 (95% confidence interval, 0.23–0.28) patients per site per month. By univariate analysis, factors associated with faster recruitment were authorization to randomize in both trials, principal investigator specialties of interventional radiology and cardiology, pre-trial reported performance >50 carotid angioplasty and stenting procedures per year, status in the top half of recruitment in the CREST trial, and classification as a private health facility. Participation in StrokeNet was associated with slower recruitment as compared with the non-StrokeNet sites. Conclusions— Overall, selection of sites with high enrollment rates will likely require customization to align the sites selected to the factor under study in the trial. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT02089217.

Objective To determine the prevalence and outcomes of intracranial aneurysm (IA) in patients with bicuspid aortic valve (BAV). Methods Retrospective review of patients with BAV who underwent brain MR angiography at the Mayo Clinic from 1994 to 2013. Results There were 678 patients included in this study—mean age 57±13 years, men 480 (71%), mean follow-up 10±3 years (5913 patient-years). Coarctation of aorta (COA) was present in 154 (23%) patients. There were 59 IAs identified in 52 of 678 patients (7.7%). IA was present in 20/154 patients (12.9%) with COA and 32/524 patients (5.7%) without COA (p<0.001). For the patients without COA, female gender and right–left cusp fusion were risks factors for IA in women after adjustment for all potential variables (HR 1.76, CI 1.31 to 2.68, p=0.03). There was no significant trend in the risk for IA across age tertiles: age ≤40 years versus 41–60 years (HR 1.19, p=0.34), and age 41–60 years versus 61–80 years (HR 1.06, p=0.56). Among the 52 patients with IA, enlargement occurred in three patients (6%), rupture in two patients (4%) and four patients (8%) underwent coil embolisation. For the 626 patients without IA at baseline, no patient developed IA over 7±2 years of imaging follow-up. Conclusions BAV is associated with a higher prevalence of IA compared to the general population, and this risk is higher in patients with COA, right–left cusp fusion and female gender.